WuXi Biologics, delivered a keynote address at the 43rd J.P. Morgan Healthcare Conference, providing an insightful look into the company’s latest achievements, strategies, and future outlook. His presentation highlighted WuXi Biologics’ significant milestones and laid out an ambitious roadmap for…
Unprecedented challenges such as conflict, climate change, epidemics, and displacement are converging to create a severe global health crisis, leaving 305 million people in dire need of humanitarian assistance in 2025. To address these challenges, the World Health Organization (WHO)…
The Nomination Committee of Orion Corporation has provided its recommendations to the company’s Board of Directors regarding proposals for the 2025 Annual General Meeting (AGM). These recommendations address both the composition of the Board of Directors and their remuneration for…
Sarclisa Secures 1st Approval in China for Relapsed/Refractory Multiple Myeloma The National Medical Products Administration (NMPA) of China has granted approval for Sarclisa (isatuximab), an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone (Pd) for the treatment of adult…
Eli Lilly and Company has announced its preliminary revenue guidance for 2024 and 2025, showcasing significant growth and momentum in its operations. For 2024, Lilly anticipates full-year worldwide revenue to reach approximately $45.0 billion, representing an impressive 32% growth compared…
Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…
Alnylam Pharmaceuticals Reports Preliminary 2024 Financials, 2025 Revenue and Pipeline Guidance Alnylam Pharmaceuticals Reports a global leader in RNA interference (RNAi) therapeutics, today released preliminary financial results for the fourth quarter and full year 2024, alongside its guidance for 2025…
Ascendis Pharma A/S has provided a comprehensive update on its business and strategic roadmap for 2025, highlighting key milestones and growth opportunities. This update was presented by Jan Mikkelsen, President and CEO, at the 43rd Annual J.P. Morgan Healthcare Conference.…
Roche Acquires Poseida Therapeutics: $9.00 per Share Tender Offer Completed Poseida Therapeutics Roche a global leader in the pharmaceutical and diagnostics industries, has announced the successful completion of its tender offer to acquire Poseida Therapeutics. This move marks a significant…
A Cautiously Optimistic Outlook for Biopharma in 2025 The biopharma sector is poised for a cautious but optimistic rebound in 2025, driven by renewed investment, the growing influence of artificial intelligence (AI), and a continued focus on late-stage assets and…
CVS Health and Aetna Allocate $750,000 in Grants to Advance Health Outcomes Across Illinois CVS Health and Aetna Better Health® of Illinois, a CVS Health company, recently announced a combined $750,000 in community grants to organizations dedicated to enhancing health…
Trispecific WuXi Biologics a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO), has announced a groundbreaking partnership with Candid Therapeutics, Inc. (“Candid”). Candid is a clinical-stage biotechnology firm aiming to lead advancements in T-cell engager therapies for autoimmune and…